Literature DB >> 21179184

Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance.

Silvia Bertagnolio1, Neil T Parkin, Michael Jordan, James Brooks, J Gerardo García-Lerma.   

Abstract

HIV-1 drug resistance genotyping is an essential component of the World Health Organization global HIV Drug Resistance (HIVDR) prevention and assessment strategy. Plasma is considered to be the most appropriate specimen type for HIV-1 drug resistance genotyping. However, use of plasma may not be feasible in rural, remote areas in resource-limited settings since its preparation and storage requires personnel and laboratory infrastructure that is often lacking. An alternative specimen type for HIVDR genotyping is dried blood spots (DBS). DBS can be made from blood drawn for routine clinical or surveillance purposes without special laboratory processing. The filter paper used is relatively inexpensive, easily obtained and stored, and although procedures for making DBS must be followed precisely, the training required is less intensive than that required for plasma separation. HIV nucleic acids are generally stable over long periods of time and freezing is not required unless storage over two weeks is planned. In addition, DBS are more easily transported than plasma because they can be shipped as non-hazardous materials using regular mail or courier services. Many studies have reported the successful genotyping of HIV-1 from DBS and some have shown a high genotypic concordance with plasma genotypes despite potential DNA interferences. During the past few years DBS have started to be widely used for HIV-1 drug resistance testing, and an increased number of reports from resource-limited areas have indicated DBS as the preferred specimen type for transmitted HIV-1 drug resistance surveillance where plasma collection is not feasible. The World Health Organization has brought together a group of experts (WHO HIVResNet DBS working group) to review current data on DBS preparation, storage, and transport conditions, and provide a reference protocol, which is also summarized in this article.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21179184

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  54 in total

1.  Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network.

Authors:  Neil Parkin; Carmen de Mendoza; Rob Schuurman; Cheryl Jennings; James Bremer; Michael R Jordan; Silvia Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings.

Authors:  Carrie Ziemniak; Yohannes Mengistu; Andrea Ruff; Ya-Hui Chen; Leila Khaki; Abubaker Bedri; Birgitte B Simen; Paul Palumbo; Susan H Eshleman; Deborah Persaud
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

3.  HemaSpot, a Novel Blood Storage Device for HIV-1 Drug Resistance Testing.

Authors:  K Brooks; A DeLong; M Balamane; L Schreier; M Orido; M Chepkenja; E Kemboi; M D'Antuono; P A Chan; W Emonyi; L Diero; M Coetzer; R Kantor
Journal:  J Clin Microbiol       Date:  2015-11-11       Impact factor: 5.948

4.  Design and implementation of an external quality assessment program for HIV viral load measurements using dried blood spots.

Authors:  Lisa M Prach; Adrian Puren; Sheri A Lippman; Sergio Carmona; Sophie Stephenson; Ewalde Cutler; Scott Barnhart; Teri Liegler
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

5.  Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.

Authors:  Marjorie Monleau; Avelin F Aghokeng; Sabrina Eymard-Duvernay; Anoumou Dagnra; Dramane Kania; Nicole Ngo-Giang-Huong; Coumba Touré-Kane; Lien X T Truong; Marie-Laure Chaix; Eric Delaporte; Ahidjo Ayouba; Martine Peeters
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

6.  Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failure.

Authors:  Paola Costenaro; Rebecca Lundin; Maria Raffaella Petrara; Martina Penazzato; William Massavon; Susan Kizito; Sandra Monica Nabachwa; Maria Nannyonga Musoke; Charles Namisi; Erika Morelli; Davide Bilardi; Antonio Mazza; Marisa Zanchetta; Carlo Giaquinto; Anita De Rossi
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

7.  Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types.

Authors:  Christina Yek; Marta Massanella; Tashi Peling; Kristen Lednovich; Sangeetha V Nair; Andrew Worlock; Milenka Vargas; Sara Gianella; Ronald J Ellis; Matthew C Strain; Michael P Busch; C Thomas Nugent; Douglas D Richman
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

8.  Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.

Authors:  J Mutsvangwa; I A Beck; L Gwanzura; M T Manhanzva; L Stranix-Chibanda; T Chipato; L M Frenkel
Journal:  J Virol Methods       Date:  2014-09-17       Impact factor: 2.014

Review 9.  Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.

Authors:  Richard J Lessells; Ava Avalos; Tulio de Oliveira
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

Review 10.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.